Fragment-based discovery of JAK-2 inhibitors
- Bioorg Med Chem Lett. 2009 Jan 1;19(1):279-82. doi: 10.1016/j.bmcl.2008.08.064.
Affiliations
- 1. Medicinal Chemistry, SGX Pharmaceuticals, Inc, San Diego, CA 92121, USA.
PMID: 19019674
DOI: 10.1016/j.bmcl.2008.08.064
Abstract
Fragment-based hit identification coupled with crystallographically enabled structure-based drug design was used to design potent inhibitors of JAK-2. After two iterations from fragment 1, we were able to increase potency by greater than 500-fold to provide sulfonamide 13, a 78-nM JAK-2 inhibitor.
Products
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: JAKResearch Areas: Inflammation/Immunology